High-density lipoprotein induces proliferation and migration of human prostate androgen - Independent cancer cells by an ABCA1-dependent mechanism

Molecular Cancer Research

Volumn 8, Issue 9, 2010, Pages 1284-1294

  Sekine, Yoshitaka ^a,b   Demosky, Steve J ^a   Stonik, John A ^a   Furuya, Yosuke ^b   Koike, Hidekazu ^b   Suzuki, Kazuhiro ^b   Remaley, Alan T ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ANDROGEN; CHARCOAL; HIGH DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SCAVENGER RECEPTOR BI; SMALL INTERFERING RNA;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANDROGENS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHOLESTEROL; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SPACE; LIPOPROTEINS, HDL; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; RNA, SMALL INTERFERING; SIMVASTATIN;

BOVINAE;

EID: 77957154686     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-10-0008     Document Type: Article

References (43)

1. Hsing AW, Tsao L, Devesa SS. International trends and patterns prostate cancer incidence and mortality. Int J Cancer 2000;85:60-7.
2. Grönberg H. Prostate cancer epidemiology. Lancet 2003;361:859-64.
3. Mills PK, Beeson WL, Phillips RL, Fraser GE. Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 1989;64:598-604.
4. Giovannucci EM, Rimm EB, Colditz GA, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 1993;85:1571-9.
5. Hughes-Fulford M, Chen Y, Tjandrawinata RR. Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells. Carcinogenesis 2001;22:701-7. (Pubitemid 32447916)
6. Sekine Y, Koike H, Nakano T, Nakajima K, Suzuki K. Remnant lipoproteins stimulate proliferation and activate MAPK and Akt signaling pathways via G protein-coupled receptor in PC-3 prostate cancer cells. Clin Chim Acta 2007;383:78-84.
7. Swyer GIM. The cholesterol content of normal and enlarged prostates. Cancer Res 1942;2:372-5.
8. Acevedo HF, Campbell EA, Saier EL, et al. Urinary cholesterol. V. Its excretion in men with testicular and prostatic neoplasms. Cancer 1973;32:196-205.
9. Oh HY, Lee EJ, Yoon S, Chung BH, Cho KS, Hong SJ. Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK signal transduction. Prostate 2007;67:1061-9.
10. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009;181:1998-2008.
11. Fukuchi J, Hiipakka RA, Kokontis JM, et al. Androgenic suppression of ATP-binding cassette transporter A1 expression in LNCaP human prostate cancer cells. Cancer Res 2004;64:7682-5.
12. Remaley AT, Amar M, Sviridov D. HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications. Expert Rev Cardiovasc Ther 2008;6:1203-5.
13. Ni J, Pang ST, Yeh S. Differential retention of α-vitamin E is correlated with its transporter gene expression and growth inhibition efficacy in prostate cancer cells. Prostate 2007;67:463-71. (Pubitemid 46536940)
14. Imaizumi S, Miura S, Nakamura K, et al. Antiarrhythmogenic effect of reconstituted high-density lipoprotein against ischemia/reperfusion in rats. J Am Coll Cardiol 2008;51:1604-12.
15. Cao WM, Murao K, Imachi H, et al. A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res 2004;64:1515-21.
16. Murao K, Imachi H, Cao W, et al. High-density lipoprotein is a potential growth factor for adrenocortical cells. Biochem Biophys Res Commun 2006;344:226-32.
17. Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Rothblat GH. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003;23:712-9.
18. O'Connell BJ, Genest J, Jr. High-density lipoproteins and endothelial function. Circulation 2001;104:1978-83.
19. Nofer J, Assmann G. Atheroprotective affects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc Med 2005;15:265-71. (Pubitemid 41437910)
20. Chuanhai G, Louis ML, David TP. Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines. J Urol 2000;163:1027-32.
21. Kane LP, Mollenauer MN, Xu Z, Turck CW, Weiss A. Akt-dependent phosphorylation specifically regulates Cot induction of NF-κ B-dependent transcription. Mol Cell Biol 2002;22:5962-74.
22. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines. J Urol 2005;173:342-59.
23. Redgrave TG, Roberts DC, West CE. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem 1975;65:42-9.
24. Khovidhunkit W, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Cholesterol efflux by acute-phase high density lipoprotein: role of lecithin: cholesterol acyltransferase. J Lipid Res 2001;42:967-75.
25. Rothblat GH, Bamberger M, Phillips MC. Reverse cholesterol transport. Methods Enzymol 1986;129:628-44.
26. Suzuki K, Koike H, Matsui H, et al. Genistein, a soy isoflavone, induces glutathione peroxidase in the human prostate cancer cell lines LNCaP and PC-3. Int J Cancer 2002;99:846-52.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2ΔΔCT method. Methods 2001;25:402-8.
28. Sivaprasad U, Abbas T, Dutta A. Differential efficacy of 3-hydroxy-3- methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther 2006;5:2310-6.
29. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005;115:959-68. (Pubitemid 40489400)
30. Sone H, Shimano H, Shu M, et al. Statins downregulate ATP-binding- cassette transporter A1 gene expression in macrophages. Biochem Biophys Res Commun 2004;316:790-4.
31. Wong J, Quinn CM, Gelissen IC, Jessup W, Brown AJ. The effect of statins on ABCA1 and ABCG1 expression in human macrophages is influenced by cellular cholesterol levels and extent of differentiation. Atherosclerosis 2008;196:180-9.
32. Acton S, Rigotti A, Landschulz KT. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996;271:518-20.
33. Freeman MR, Solomon KR. Cholesterol and prostate cancer. J Cell Biochem 2004;91:54-69.
34. Kimura T, Sato K, Kuwabara A, et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem 2001;276:31780-5.
35. Miura S, Fujino M, Matsuo Y, et al. High density lipoprotein-induced angiogenesis requires the activation of Ras/MAP kinase in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol 2003;23:802-8.
36. Mineo C, Yuhanna IS, Quon MJ, Shaul PW. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem 2003;278:9142-9.
37. Gibbs TC, Rubio MV, Zhang Z, Xie Y, Kipp KR, Meier KE. Signal transduction responses to lysophosphatidic acid and sphingosine 1-phosphate in human prostate cancer cells. Prostate 2009;69:1493-506.
38. Okajima F, Sato K, Kimura T. Anti-atherogenic actions of high-density lipoprotein through sphingosine 1-phosphate receptors and scavenger receptor class B type I. Endocr J 2009;56:317-34.
39. Shannon J, Tewoderos S, Garzotto M, et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005;162:318-25. (Pubitemid 41389713)
40. Platz EA, Leitzmann MF, Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006;98:1819-25.
41. Cafforio P, Dammacco F, Gernone A, Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 2005;26:883-91.
42. Meyers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol 2004;15:659-65.
43. Langer C, Gansz B, Goepfert C, et al. Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun 2002;296:1051-7.